Benign prostatic hyperplasia
Benign overgrowth of prostate tissue leading to difficulty urinating. Alpha-blockers relax smooth muscle in the prostate and bladder neck, relieving symptoms.
ICD-10 N4013 drugs
Also known as: BPH, Prostate adenoma, Prostatic hypertrophy
Drugs used for this condition
- ADoxazosinFirst line · Long-acting selective α1-adrenoceptor antagonistFirst-line for symptomatic benign prostatic hyperplasia per EAU 2024 alongside tamsulosin, silodosin, and alfuzosin. Dose 4–8 mg once daily (GITS form). Effective on IPSS and Qmax. In patients with concomitant hypertension, adds antihypertensive effect.
- ADutasterideFirst line · Testosterone 5α-reductase types 1 and 2 inhibitorsDutasteride 0.5 mg/day is first-line therapy for benign prostatic hyperplasia. The EPICS study (Andriole 2010, n=1630, head-to-head with finasteride) showed equivalence on symptoms and prostate volume. The CombAT trial (Roehrborn 2010, n=4844, 4 years) confirmed the superiority of dutasteride + tamsulosin combination over monotherapy on progression risk. AUA 2021, EAU 2023, and NICE NG97 guidelines list dutasteride as first-line for BPH with prostate volume >40 mL, equivalent to finasteride.
- ADutasteride + TamsulosinSecond line · Fixed-dose combination: 5-alpha-reductase inhibitor plus selective alpha-1a-adrenoceptor blockerBenign prostatic hyperplasia in men with moderate-to-severe symptoms (IPSS ≥8), enlarged prostate (≥30 mL), and progression risk. Per EAU 2024 – second-line after alpha-blocker or 5-alpha-reductase inhibitor monotherapy. Dose: 0.5/0.4 mg once daily 30 minutes after a meal. Tamsulosin effect at 1–2 weeks, dutasteride at 3–6 months. PSA falls by 50% – adjust for this when interpreting results.
- AFinasterideFirst line · Testosterone 5α-reductase type 2 inhibitorsFinasteride 5 mg/day is evidence-based first-line therapy for benign prostatic hyperplasia with prostate volume above 30–40 mL. The PLESS trial (Roehrborn 2002, n=3040, 4 years) showed 57% reduction in acute urinary retention risk and 55% reduction in surgery need versus placebo. Prostate volume shrinks by 20–25%, PSA by about 50% (important for prostate cancer screening interpretation). Effect develops over 6–12 months. Combination with α-blockers (tamsulosin, doxazosin) provides additional benefit on symptoms and progression risk (MTOPS, CombAT). AUA, EAU, and NICE guidelines list finasteride as first-line for obstructive BPH with enlarged prostate.
- ASilodosinFirst line · Highly selective α1A-adrenergic blockerFirst-line for symptomatic benign prostatic hyperplasia with moderate-to-severe symptoms per EAU 2024 alongside tamsulosin and alfuzosin. Dose 8 mg once daily. Effective on IPSS and Qmax. Particularly suitable in patients with orthostatic hypotension risk factors – less BP drop than tamsulosin. Does not reduce prostate size – with a large gland, combine with a 5α-reductase inhibitor (finasteride, dutasteride).
- ATadalafilSecond line · Phosphodiesterase type 5 (PDE-5) inhibitorUsed in symptomatic benign prostatic hyperplasia in patients with concomitant erectile dysfunction per EAU 2024. Dose 5 mg once daily. Effect on IPSS and Qmax is comparable to tamsulosin, with less retrograde ejaculation. Dual benefit in coexisting conditions makes tadalafil a preferred choice in this group.
- ATamsulosinFirst line · Alpha-adrenergic blockers for prostatic disordersFirst-line medical therapy for BPH per EAU 2023 and AUA guidelines. Dose is 0.4 mg once daily. Effect begins within 1–2 weeks. Improves Qmax (peak urinary flow rate) by 1–3 mL/s and reduces IPSS score by 3–5 points. Does not reduce prostate volume – a 5-alpha-reductase inhibitor (finasteride, dutasteride) is added when prostate volume exceeds 40 mL.
- CPumpkin seed extractAdd-on therapy · Botanical supplement, pumpkin seed extract (Cucurbita pepo); EMA HMPC traditional-use herbal medicinal product for BPH symptoms and overactive bladder; sold on iHerb and Amazon for «prostate health» and women's «urinary comfort»Pumpkin seed extract is an over-the-counter herbal remedy. The Bach prospective 3-year study (Urologe A 2000) in 2245 men with BPH used Prosta Fink Forte 500–1000 mg/day: IPSS dropped by 41% on average, post-void residual decreased and tolerability was good, but the design lacked placebo control. The Vahlensieck double-blind RCT (Urol Int 2015) in 1431 men compared Granu Fink Prosta forte standardised extract with placebo over 12 months: IPSS reduction was 6.8 points in the active arm vs 5.5 in placebo (statistically significant but clinically small). EMA HMPC 2012 recognises pumpkin seed as a traditional-use medicinal product for lower urinary tract symptoms in BPH based on 30 years of use, not RCTs. EAU 2024, AUA 2023 and AEU 2022 recommend alpha-blockers and 5-alpha-reductase inhibitors for moderate-severe BPH; herbal products are mentioned as an option for mild symptoms or add-on to standard therapy. If pumpkin seed extract is being considered, discuss with a urologist and have a PSA test to rule out prostate cancer.
- CPumpkin seed oil (Cucurbita pepo, Cucurbita maxima)Add-on therapy · Plant product, supplement. In EU – traditional herbal medicinal product per EMA HMPC monograph; AEMPS does not register as monomedicineIn mild-to-moderate benign prostatic hyperplasia, Sogabe 2009 RCT (n=47, Korean men) and the larger Vahlensieck 2015 study (n=1431, German Pumpkin Study) showed moderate IPSS reduction of 4–6 points with pumpkin seed oil 320–1000 mg/day × 12 months vs placebo. The effect is clinically smaller than alpha-1 blockers (tamsulosin, silodosin). AUA 2023 and EAU 2024 list alpha-1 blockers (tamsulosin, silodosin) first-line for male LUTS with BPH; with prostate volume >40 mL and progression risk – 5-alpha-reductase inhibitors (finasteride, dutasteride). EMA HMPC 2012 recognises «traditional use for BPH symptoms». If pumpkin seed oil was recommended for severe symptoms with urinary retention or after acute retention, consider seeking a second opinion from a urologist.
- CPygeum africanumAdd-on therapy · Botanical supplement, bark extract of African plum (Prunus africana); EMA HMPC traditional-use herbal medicinal product for BPH symptoms; popular iHerb and Amazon «prostate health» categoryPygeum is an over-the-counter herbal extract. The Cochrane Wilt review (2002) pooled 18 RCTs with 1562 men with BPH: Prunus africana extract 75–200 mg/day for 4–16 weeks moderately reduced nocturia (-19% vs placebo), improved peak urinary flow (+23%) and lowered total symptom score. The effect is modest and comparable to weak alpha-blockers in small samples; no high-quality large RCTs against tamsulosin or finasteride exist. EMA HMPC 2014 recognises Prunus africana bark as a traditional-use medicinal product for BPH symptoms, based on 30 years of use rather than RCTs. EAU 2024, AUA 2023 and AEU 2022 recommend watchful waiting and lifestyle changes for mild BPH (IPSS <8) and alpha-blockers (tamsulosin, silodosin), 5-alpha-reductase inhibitors (finasteride, dutasteride) or combinations for moderate-severe symptoms (IPSS 8–19 and higher). Pygeum is mentioned as an option for mild symptoms or as add-on to standard therapy, not as a substitute for prescription drugs. If pygeum was prescribed or you want to try it, discuss with a urologist and have a PSA and digital rectal exam to avoid missing prostate cancer hidden behind «BPH».
- CStinging nettle root (Urtica dioica, radix)Add-on therapy · Plant extract, supplement. In EU – traditional herbal medicinal product per EMA HMPC monograph 2010 for BPH symptoms; AEMPS does not register as monomedicineNettle root is an over-the-counter herbal remedy used for BPH in Germany for decades. The double-blind RCT by Sokeland (BJU Int 2000) in 543 men compared a combination of nettle root and saw palmetto extract with finasteride 5 mg/day: at 48 weeks IPSS and urinary flow improvements were comparable in both groups, with better tolerability of the combination, but the study lacked placebo control and was sponsored. The Safarinejad RCT (2005) in 620 men using nettle root alone 120 mg twice daily for 6 months showed modest IPSS reduction (-3.4 vs -0.8 with placebo) and improved quality of life. EMA HMPC 2012 recognises nettle root as a traditional-use medicinal product for BPH symptoms, based on 30 years of use rather than RCTs. EAU 2024, AUA 2023 and AEU 2022 recommend alpha-blockers and 5-alpha-reductase inhibitors for moderate-severe BPH; herbal products are mentioned as an option for mild symptoms or as add-on. If nettle root is being considered, discuss with a urologist and have a PSA test. Check the label for Urtica dioica radix (not folium).
Marketing claims without evidence base
The drug is promoted for these uses outside international guidelines. Each entry below is analyzed against AEMPS, FDA, EMA, Cochrane and major RCTs.
- DLycopeneNot recommended · Tetraterpene carotenoid; pigment of tomatoes, rosehip, watermelon and grapefruit; sold as a supplement and as the food colorant E160d; not registered as a medicine by AEMPSLycopene is heavily marketed as a «prostate health support» for benign prostatic hyperplasia. No quality RCTs with urological endpoints (IPSS, post-void residual volume, flow rate) exist – only small trials with conflicting results. EFSA 2011 rejected health claims linking lycopene to prostate function. EAU 2024 and AEU 2023 do not include lycopene in BPH algorithms: the first line consists of alpha-blockers (tamsulosin, silodosin), 5-alpha-reductase inhibitors (finasteride, dutasteride) and, when indicated, PDE-5 inhibitors (tadalafil). Lower urinary tract symptoms require in-person urology assessment with PSA and ultrasound, not self-prescribed lycopene from iHerb.
- DSaw palmetto (Serenoa repens)Not recommended · Dietary supplements and phytotherapeutics, sabal palm fruit extracts (local classification)Saw palmetto has been marketed for decades as a herbal remedy for benign prostatic hyperplasia. The largest Cochrane update 2012 (Tacklind, 32 RCTs, n=5666) showed no significant benefit over placebo on urinary symptoms (IPSS score), post-void residual urine volume, or maximum flow rate. STEP (n=225) and CAMUS (n=369) trials also showed no effect. AUA 2021 guidelines classify saw palmetto as «failed to demonstrate efficacy» – not recommended. EAU 2023 guidelines permit Permixon extract as an option for mild symptoms.
How to read tiers A–F
Evidence tiers belong to the drug-indication pair, not to the drug as a whole: the same substance can be A for one condition and F for another.
- AStrong evidence – first or second line in international guidelines
- BRecommended in selected cases
- CStudy data contradict each other
- DBenefit not proven, no documented harm
- FDocumented harm, or risk without benefit